Patients
NRAS, MSI
ONCOLOGY, DISEASE
Eligible patients must have histologically or cytologically confirmed metastatic CRC, have a documented BRAF V600E mutation by a CLIA-certified laboratory test and be wild type for KRAS and NRAS. Patients were required to be aged ≥18 years, have measurable disease according to RECIST v.1.1, have an Eastern Cooperative Oncology Group performance status of less than or equal to two and have adequate baseline organ function (as determined by laboratory parameters). The first patient was enrolled on 15 October 2018. The trial was amended after the first nine patients to exclude patients with prior BRAF or MEK inhibitor or immunotherapy, and this amendment was Institutional Review Board approved. Enrollment of the remaining slots reserved for patients with MSI on the trial is still ongoing at this time. Key exclusion criteria included chemotherapy or radiotherapy within 4 weeks prior to entering the study and any serious or unstable preexisting medical condition. All patients provided written informed consent before the study.